• Friday, 14 September 2012
  • Saturday, 15 September 2012
  • Sunday, 16 September 2012
General Session
State-of-the-Art Lecture
Symposium
Industry Symposium
Workshop
TIME
08:00
09:30
ILCA Symposium 1
Identification of Molecular Drivers with New Technologies in Liver Cancer

Chair: Jessica Zucman-Rossi, MD, PhD (France)Identification of Molecular Drivers with New Technologies in Liver Cancer
Xin Wang, MD, PhD (USA)Hydrodynamic Gene Delivery: A Powerful Tool to Investigate the Molecular Pathogenesis of Liver Cancer
Diego Calvisi, MD (Germany)RNAi Based Functional Genomic Approaches for Accelerated Cancer Gene Discovery in Liver Cancer
Lars Zender, MD (Germany)
09:30
10:30
State-of-the-Art Lecture 1
Novel Concepts in Epidemiology and Surveillance in HCC
Chair: Guido Gerken, MD (Germany)
Speaker: Massimo G. Colombo, MD (Italy)
10:30
11:00
Coffee and Networking Break
11:00
11:15
Opening Ceremony
Josep M. Llovet, MD (Spain/USA)
Riccardo Lencioni, MD (Italy)
Peter R. Galle, MD (Germany)
11:15
12:45
General Session 1
Molecular Pathogenesis of Liver Cancer
Chairs: Curtis Harris, MD, PhD (USA) and Lewis Roberts, MB, ChB, PhD (USA)
12:45
13:00
Session Break
13:00
14:30
Bayer Satellite Symposium
14:30
14:45
Session Break
14:45
16:15
General Session 2
Epidemiology and Surgical Management
Chairs: Kim Olthoff, MD (USA) and Hauke Lang, MD, MA, FACS (Germany)
16:15
18:15
ILCA Symposium 2
Controversies in Liver Cancer (Pros and Cons Session)
Chairs: Ronnie Poon, MD (China) and Philippe Merle, MD (France)
Should We Use AFP for Surveillance?
Morris Sherman, MD (Canada) vs. Jorge Marrero, MD (USA)
Should We Take Biopsies from all HCC Patients?
Peter Galle, MD (Germany) vs. Michel Beaugrand, MD (France)
Is There an Indication for Y90 in the Treatment of HCC?
Riad Salem, MD (USA) vs. Jordi Bruix, MD (Spain)
18:15
19:00
Welcome Reception
TIME
07:30
08:30
Novartis Symposium
08:30
10:00
General Session 3
Loco-regional Therapies and Response Assessment
Chairs: Riccardo Lencioni, MD (Italy) and Masatoshi Kudo, MD, PhD (Japan)
10:00
10:30
Coffee and Networking Break
10:30
12:00
Plenary Session
Chairs: Josep M. Llovet, MD (Spain/USA) and Peter R. Galle, MD (Germany)
12:00
12:15
Session Break
12:15
13:30
Luncheon Workshop 1
Liver Biopsy: Is It Still Useful?
Chairs: Pierre Bedossa, MD, PhD (France) and Masatoshi Kudo, MD, PhD (Japan)Luncheon Workshop 2
Resection vs. Transplant for Non-HCC Malignancies
Chairs: Jacques Belghiti, MD (France) and Vincenzo Mazzaferro, MD (Italy) Luncheon Workshop 3
Linking Signaling Pathways and Novel Therapies in HCC
Jean-François Dufour, MD (Switzerland) and Augusto Villanueva, MD (Spain) Luncheon Workshop 4
Management of Cholangiocarcinoma
Myron Schwartz, MD (USA) and Gregory Gores, MD (USA)Luncheon Workshop 5
Experimental Models in Liver Cancer
Lars Zender, MD (Germany) and Peter Schirmacher, MD (Germany)
13:30
13:45
Session Break
13:45
15:15
ILCA Symposium 3

New Compounds in Early Clinical Trials in HCC
Chairs: Josep M. Llovet, MD (Spain/USA)

Rationale for Exploring Novel Drugs in Second Line for Advanced Hcc
Andrew X. Zhu, MD, PhD (USA)

Trial Design and Novel Drugs in First Line of HCC
Philip Johnson, MD (UK)

Why Molecular Targeted Therapies Fail in Randomized Control Trials
Ann-Lii Cheng, MD, PhD (Taiwan)

15:15
16:15
Coffee, Networking Break and e-Poster Viewing Session
16:15
17:45
General Session 4
Drivers, Biomarkers and Novel Therapeutics
Chairs: Gregory Gores, MD (USA) and Pierre Bedossa, MD, PhD (France)
17:45
18:45
Sirtex Symposium
TIME
08:30
09:00
ILCA General Assembly
09:00
09:30
Coffee and Networking Break
09:30
10:30
State-of-the-Art Lecture 2
Human Cancer Epigenetics and Beyond
Chair: Lewis Roberts, MB, ChB, PhD (USA)
Speaker: Manel Esteller, MD, PhD (Spain)
10:30
12:00
General Session 5
Clinical Trials
Chairs: Sandrine Faivre, MD, PhD (France) and Joong-Won Park, MD, PhD (Korea)
12:00
12:45
Closing Ceremony and Junior Investigator Awards
Josep M. Llovet, MD (Spain/USA)